FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206788891> ?p ?o ?g. }

• W4206788891 abstract "Background Antipsychotic drugs are the mainstay treatment for schizophrenia. Long‐acting depot injections of drugs such as bromperidol decanoate are extensively used as a means of long‐term maintenance treatment. Objectives To assess the effects of depot bromperidol versus placebo, oral antipsychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes. Search methods Relevant trials were identified by searching Biological Abstracts (1982‐1999), Cochrane Library (Issue 2, 1999), Cochrane Schizophrenia Group's Register (May 1999), EMBASE (1980‐1999), MEDLINE (1966‐1999) and PsycLIT (1974‐1999). References of all identified trials were inspected and Janssen‐Cilag was contacted in order to identify more trials. An update search was undertaken in October 2003. The Schizophrenia Groups trials register is based on regular searches of BIOSIS Inside; CENTRAL; CINAHL; EMBASE; MEDLINE and PsycINFO; the hand searching of relevant journals and conference proceedings, and searches of several key grey literature sources. A full description is given in the Group's module. Selection criteria All randomised trials focusing on people with schizophrenia where depot bromperidol, oral antipsychotics or other depot preparations were sought. Primary outcomes were death, clinically significant change in global function, mental state, relapse, hospital admission, adverse effects and acceptability of treatment. Data collection and analysis Data were extracted independently by two reviewers and cross‐checked. Fixed effects relative risks (RR) and 95% confidence intervals (CI) were calculated for dichotomous data. Weighted or standardised means were calculated for continuous data. Where possible, the number needed to treat statistic (NNT) was calculated. Analysis was by intention‐to‐treat. Main results Four controlled clinical trials were included (total n=117). We identified a single small study of six months duration comparing bromperidol decanoate with placebo injection. Similar numbers left the study before completion (n=20, 1 RCT, RR 0.4 CI 0.1 to 1.6) and there was no clear differences between bromperidol decanoate and placebo for a list of adverse effects (n=20, 1 RCT, RR akathisia 2.0 CI 0.21 to 18.69, RR increased weight 3.0 CI 0.14 to 65.9, RR tremor 0.33 CI 0.04 to 2.69). When bromperidol decanoate was compared with fluphenazine depot we found no important change on global outcome (n=30, RR no clinical important improvement 1.50 CI 0.29 to 7.73). People allocated to fluphenazine decanoate and haloperidol decanoate had less relapses than those given bromperidol decanoate (n=77, RR 3.92 Cl 1.05 to 14.60, NNH 6 CI 2 to 341). People allocated bromperidol decanoate required additional antipsychotic medication somewhat more frequently than those taking fluphenazine decanoate and haloperidol decanoate but the results did not reach conventional levels of statistical significance (n=77, 2 RCTs, RR 1.72 CI 0.7 to 4.2). The use of benzodiazepine drugs was very similar in both groups (n=77, 2 RCTs, RR 1.08 CI 0.68 to 1.70). People left the bromperidol decanoate group with the same frequency as those allocated other depots (n=97, 3 RCTs, RR 1.92 CI 0.8 to 4.6). Anticholinergic adverse effects were equally common between bromperidol and other depots (n=47, RR 3.13 CI 0.7 to 14.0) and additional anticholinergic medication was needed with equal frequency in both depot groups, although results did tend to favour the bromperidol decanoate group (n=97, 3 RCTs, RR 0.80 CI 0.64 to 1.01). The incidence of movement disorders was similar in both depot groups (n=77, 2 RCTs, RR 0.74 CI 0.47 to 1.17). Authors' conclusions Currently, minimal poorly reported trial data suggests that bromperidol decanoate may be better than placebo injection but less valuable than fluphenazine or haloperidol decanoate. If bromperidol decanoate is available it may be a viable choice, especially when there are reasons not to use fluphenazine or haloperidol decanoate. Well‐conducted and reported randomised trials are needed to inform practice in Belgium, Germany, Italy and the Netherlands." @default.
• W4206788891 created "2022-01-25" @default.
• W4206788891 creator A5005500708 @default.
• W4206788891 creator A5011682364 @default.
• W4206788891 creator A5085074957 @default.
• W4206788891 date "2004-07-19" @default.
• W4206788891 modified "2023-09-24" @default.
• W4206788891 title "Depot bromperidol decanoate for schizophrenia" @default.
• W4206788891 cites W1591259115 @default.
• W4206788891 cites W1971251178 @default.
• W4206788891 cites W1971785694 @default.
• W4206788891 cites W1977185679 @default.
• W4206788891 cites W1978040764 @default.
• W4206788891 cites W2017084996 @default.
• W4206788891 cites W2037507227 @default.
• W4206788891 cites W2052137437 @default.
• W4206788891 cites W2058874144 @default.
• W4206788891 cites W2068448581 @default.
• W4206788891 cites W2074021723 @default.
• W4206788891 cites W2076160404 @default.
• W4206788891 cites W2090989307 @default.
• W4206788891 cites W2125435699 @default.
• W4206788891 cites W2134338262 @default.
• W4206788891 cites W2137619119 @default.
• W4206788891 cites W2152240392 @default.
• W4206788891 cites W2153190128 @default.
• W4206788891 cites W2157823046 @default.
• W4206788891 cites W2327559947 @default.
• W4206788891 cites W2413424056 @default.
• W4206788891 cites W2414839572 @default.
• W4206788891 cites W2430522973 @default.
• W4206788891 cites W2742901283 @default.
• W4206788891 cites W2743099876 @default.
• W4206788891 cites W2744310387 @default.
• W4206788891 cites W4233954896 @default.
• W4206788891 cites W4320288061 @default.
• W4206788891 doi "https://doi.org/10.1002/14651858.cd001719.pub2" @default.
• W4206788891 hasPublicationYear "2004" @default.
• W4206788891 type Work @default.
• W4206788891 citedByCount "2" @default.
• W4206788891 crossrefType "reference-entry" @default.
• W4206788891 hasAuthorship W4206788891A5005500708 @default.
• W4206788891 hasAuthorship W4206788891A5011682364 @default.
• W4206788891 hasAuthorship W4206788891A5085074957 @default.
• W4206788891 hasConcept C118552586 @default.
• W4206788891 hasConcept C126322002 @default.
• W4206788891 hasConcept C142724271 @default.
• W4206788891 hasConcept C17744445 @default.
• W4206788891 hasConcept C197934379 @default.
• W4206788891 hasConcept C199539241 @default.
• W4206788891 hasConcept C204787440 @default.
• W4206788891 hasConcept C27081682 @default.
• W4206788891 hasConcept C27415008 @default.
• W4206788891 hasConcept C2776412080 @default.
• W4206788891 hasConcept C2776478404 @default.
• W4206788891 hasConcept C2779473830 @default.
• W4206788891 hasConcept C2779549880 @default.
• W4206788891 hasConcept C2780494398 @default.
• W4206788891 hasConcept C2781145037 @default.
• W4206788891 hasConcept C44249647 @default.
• W4206788891 hasConcept C535046627 @default.
• W4206788891 hasConcept C67774102 @default.
• W4206788891 hasConcept C71924100 @default.
• W4206788891 hasConcept C82789193 @default.
• W4206788891 hasConcept C95190672 @default.
• W4206788891 hasConceptScore W4206788891C118552586 @default.
• W4206788891 hasConceptScore W4206788891C126322002 @default.
• W4206788891 hasConceptScore W4206788891C142724271 @default.
• W4206788891 hasConceptScore W4206788891C17744445 @default.
• W4206788891 hasConceptScore W4206788891C197934379 @default.
• W4206788891 hasConceptScore W4206788891C199539241 @default.
• W4206788891 hasConceptScore W4206788891C204787440 @default.
• W4206788891 hasConceptScore W4206788891C27081682 @default.
• W4206788891 hasConceptScore W4206788891C27415008 @default.
• W4206788891 hasConceptScore W4206788891C2776412080 @default.
• W4206788891 hasConceptScore W4206788891C2776478404 @default.
• W4206788891 hasConceptScore W4206788891C2779473830 @default.
• W4206788891 hasConceptScore W4206788891C2779549880 @default.
• W4206788891 hasConceptScore W4206788891C2780494398 @default.
• W4206788891 hasConceptScore W4206788891C2781145037 @default.
• W4206788891 hasConceptScore W4206788891C44249647 @default.
• W4206788891 hasConceptScore W4206788891C535046627 @default.
• W4206788891 hasConceptScore W4206788891C67774102 @default.
• W4206788891 hasConceptScore W4206788891C71924100 @default.
• W4206788891 hasConceptScore W4206788891C82789193 @default.
• W4206788891 hasConceptScore W4206788891C95190672 @default.
• W4206788891 hasLocation W42067888911 @default.
• W4206788891 hasOpenAccess W4206788891 @default.
• W4206788891 hasPrimaryLocation W42067888911 @default.
• W4206788891 hasRelatedWork W2052353580 @default.
• W4206788891 hasRelatedWork W2119650801 @default.
• W4206788891 hasRelatedWork W2767101331 @default.
• W4206788891 hasRelatedWork W2981900262 @default.
• W4206788891 hasRelatedWork W3016761009 @default.
• W4206788891 hasRelatedWork W3018781222 @default.
• W4206788891 hasRelatedWork W3035277694 @default.
• W4206788891 hasRelatedWork W3036778824 @default.
• W4206788891 hasRelatedWork W4225116982 @default.
• W4206788891 hasRelatedWork W4294126851 @default.
• W4206788891 isParatext "false" @default.

• next